• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cuvposa (glycopyrrolate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cuvposa (glycopyrrolate)

  • Profile

Profile

Contact Information

Contact: Merz Pharmaceuticals
Website: www.cuvposa.com

Currently Enrolling Trials

    Show More

    General Information

    Cuvposa (glycopyrrolate) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.

    Cuvposa is specifically indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling.

    Cuvposa is supplied as a liquid solution for oral administration. The recommended initial dose is 0.02 mg/kg orally three times daily. The dosing may be titrated in increments of 0.02 mg/kg every 5-7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5-3 mg per dose based upon weight.

    Mechanism of Action

    Cuvposa (glycopyrrolate) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.

    Side Effects

    Adverse events associated with the use of Cuvposa may include, but are not limited to, the following:

    • Dry mouth
    • Vomiting
    • Constipation
    • Flushing
    • Nasal congestion

    Clinical Trial Results

    The FDA approval of Cuvposa was based on a multi-center, randomized, double-blind, placebo-controlled, parallel, eight-week study in 38 subjects aged 3-23 years. Of these 38 subjects, 36 were ages were ages 2 - 16 years and two subjects were older than 16 years. All subjects had a diagnosis of cerebral palsy, mental retardation, or another neurologic condition associated with problem drooling, defined as drooling in the absence of treatment so that clothing became damp on most days (approximately five to seven days per week). The subjects received receive Cuvposa or placebo. Doses of Cuvposa were titrated over a 4-week period to optimal response beginning at 0.02 mg/kg given three times a day increasing doses in increments of approximately 0.02 mg/kg three times per day every 5-7 days, not to exceed the lesser of approximately 0.1 mg/kg three times per day or 3 mg three times per day. Efficacy was evaluated on the 9-point modified Teacher's Drooling Scale (mTDS). Scores were recorded by parents/caregivers three times daily approximately two hours post-dose on beginning at pre-treatment baseline and at Weeks 2, 4, 6 and 8 of therapy. A score of 1 meant Dry: never drools and a score of 9 meant Profuse: clothing, hands, tray and objects become wet; frequently. Responders were defined as subjects with at least a 3-point reduction in mean daily mTDS scores from baseline to Week 8. In the Cuvposa treatment arm, 75% of the patients were responders versus 11% in the placebo arm.

    Approval Date: 2010-07-01
    Company Name: Merz Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing